Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of giving pemetrexed disodium and
sorafenib tosylate together in treating patients with advanced solid tumors. Pemetrexed
disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of solid tumors
by blocking blood flow to the tumor. Giving pemetrexed disodium together with sorafenib
tosylate may kill more tumor cells.